Clinical Trials · NCT04552847
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
- Phase
- Phase 2/Phase 3
- Recruitment status
- Completed
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Enrollment
- 85
- Start date
- Oct 2020
- Locations
- 1 site, Belgium
- Primary endpoint
- Differential detection ratio (DDR)